Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
February 15, 2023 11:30 ET
|
Psycheceutical Bioscience, Inc.
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in AustraliaPhase I trial will study 20 people to test the safety, tolerability,...
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
February 02, 2023 10:20 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
Irwin Naturals Secures $40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million
February 02, 2023 07:30 ET
|
Irwin Naturals
LOS ANGELES, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today that the Company has secured a credit facility as of...
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
January 30, 2023 07:30 ET
|
Irwin Naturals
Strategic transaction assembles an experienced management and scientific team world-renowned in the mental health treatment, research and development.Establishes large footprint of 22 specialized...
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
January 27, 2023 07:30 ET
|
Irwin Naturals
Strategic transaction assembles an experienced management and scientific team world-renowned in the mental health treatment, research and development.Establishes large footprint of 17 specialized...
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
January 26, 2023 12:15 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for...
Cambridge Biotherapies Opening New Mental Health Treatment Center Offering Psychedelic Therapy, TMS, and More in Amherst, Massachusetts
December 13, 2022 11:00 ET
|
Cambridge Biotherapies
AMHERST, Mass., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cambridge Biotherapies, the Boston area's preeminent mental health care clinic, announced the opening of a new location in Amherst, Massachusetts....
The Addition of Three Mental Health Clinics to Irwin Naturals' Florida Footprint Solidifies the Companies Impact as One of the Fastest-Growing Chains of Mental Health Clinics
December 09, 2022 07:30 ET
|
Irwin Naturals
LOS ANGELES, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a...
Irwin Naturals Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics
November 30, 2022 07:30 ET
|
Irwin Naturals
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it reached a binding, arms-length, agreement to...